PO.CL08.01 · 临床研究

部分肿瘤放射暴露后STING的激活

Activation of STING in response to partial-tumor radiation exposure

编号 6601 展板 2 时间 4/21 02:00–05:00 区域 Section 46 主讲 Adriana Haimovitz-Friedman, PhD
分会场 Radiation and Photodynamic Therapy Response Modifiers
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Mickael Mathieu1, Sadna Budhu2, Prerna R. Nepali3, James Russell4, Simon N. Powell5, John L. Humm4, Joseph O. Deasy4, Adriana NA Haimovitz-Friedman1

1Memorial Sloan Kettering Cancer Center, New york, NY,2Immunology, Memorial Sloan Kettering Cancer Center, New York, NY,3Memorial Sloan Kettering Cancer Center, Fort Lee, NJ,45Memorial Sloan Kettering Cancer Center, New York, NY

摘要 Abstract

中文摘要
目的:确定部分体积放疗(RT)诱导肿瘤反应所涉及的机制。 方法与材料:我们研究了Balb/c小鼠中的67NR小鼠原位乳腺肿瘤,以及注射到C57Bl/6、cGAS或STING KO小鼠胁部的Lewis肺癌(LLC细胞;WT、CRISPR/Cas9 Sting KO和Atm KO)。使用微照射器上的2X2 cm准直器将RT递送至50%或100%的肿瘤体积,以实现精确照射。在RT后不同时间点采集肿瘤和血液,评估细胞因子测量值。 结果:与对照及100%暴露的67NR肿瘤相比,半照射肿瘤中cGAS/STING通路存在显著激活。在LLC模型中,我们确定涉及ATM介导的STING非经典激活。我们证明部分暴露RT介导的免疫反应依赖于肿瘤细胞中的ATM激活以及宿主中的STING激活,而cGAS则可有可无。我们的结果还表明,与100%肿瘤体积暴露相比,部分体积RT刺激了不同的细胞因子表达。 结论:部分体积RT通过激活STING诱导抗肿瘤反应,STING刺激作为免疫反应一部分的特定细胞因子特征。然而,这种STING激活的机制——是通过经典cGAS/STING通路还是通过非经典ATM驱动通路——取决于肿瘤类型。在不同肿瘤类型中鉴定部分RT介导免疫反应中负责STING激活的上游通路,将改善该疗法及其与免疫检查点阻断和其他抗肿瘤疗法潜在联合的效果。
查看英文原文 English abstract
Purpose: To determine the mechanisms involved in partial volume radiation therapy (RT)-induced tumor response. Methods and Materials: We investigated 67NR murine orthotopic breast tumors in Balb/c mice and Lewis lung carcinoma (LLC cells; WT, Crispr/Cas9 Sting KO and Atm KO) injected in the flank of C57Bl/6, cGAS or STING KO mice. RT was delivered to 50% or 100% of the tumor volume using a 2X2 cm collimator on a microirradiator allowing precise irradiation. Tumors and blood were collected at different time points post-RT and assessed for cytokine measurements. Results: There is a significant activation of the cGAS/STING pathway in the hemi-irradiated tumors as compared to control and to 100% exposed 67NR tumors. In the LLC model, we determined that an ATM-mediated non-canonical activation of STING is involved. We demonstrated that the partial exposure RT-mediated immune response is dependent on ATM activation in the tumor cells and on the STING activation in the host, while cGAS is dispensable. Our results also indicate that partial volume RT stimulates a different cytokine expression as compared to 100% tumor volume exposure. Conclusion: Partial volume RT induces an anti-tumor response by activating STING which stimulates a specific cytokine signature as part of the immune response. However, the mechanism of this STING activation, via the canonical cGAS/STING pathway or a non-canonical ATM-driven pathway, depends on the tumor type. Identifying the upstream pathways responsible for STING activation in the partial RT-mediated immune response in different tumor types would improve this therapy and its potential combination with immune checkpoint blockade and other anti-tumor therapies.
利益披露 Disclosure
M. Mathieu, None.. A. N. Haimovitz-Friedman, None.

← 返回 AACR 2026 检索